BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Magro F, Rodrigues A, Vieira AI, Portela F, Cremers I, Cotter J, Correia L, Duarte MA, Tavares ML, Lago P, Ministro P, Peixe P, Lopes S, Garcia EB. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis. 2012;18:573-583. [PMID: 21793126 DOI: 10.1002/ibd.21815] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Burisch J, Ungaro R, Vind I, Prosberg MV, Bendtsen F, Colombel JF, Vester-Andersen MK. Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort. J Crohns Colitis 2017;11:1200-4. [PMID: 28486626 DOI: 10.1093/ecco-jcc/jjx066] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
2 Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, Talar-Wojnarowska R. Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment. J Clin Med 2021;10:5660. [PMID: 34884361 DOI: 10.3390/jcm10235660] [Reference Citation Analysis]
3 Chartier LC, Howarth GS, Trinder D, Mashtoub S. Emu oil and grape seed extract reduce tumour burden and disease parameters in murine colitis-associated colorectal cancer. Carcinogenesis 2021;42:202-9. [PMID: 32940671 DOI: 10.1093/carcin/bgaa099] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Manetti N, Bagnoli S, Rogai F, Bonanomi AG, Vannozzi G, Giannotta M, Annese V. Disease Course and Colectomy Rate of Ulcerative Colitis: A Follow-up Cohort Study of a Referral Center in Tuscany. Inflamm Bowel Dis 2016;22:1945-53. [PMID: 27104823 DOI: 10.1097/MIB.0000000000000787] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
5 Fernández-clotet A, Castro-poceiro J, Panés J. Tofacitinib for the treatment of ulcerative colitis. Expert Review of Clinical Immunology 2018;14:881-92. [DOI: 10.1080/1744666x.2018.1532291] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
6 Rai T, Choudhury BN, Kedia S, Bopanna S, Venigalla PM, Garg SK, Singla V, Makharia G, Ahuja V. Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience. Dig Dis Sci. 2017;62:1025-1034. [PMID: 28161855 DOI: 10.1007/s10620-017-4450-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
7 Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94:1357-1373. [PMID: 31272578 DOI: 10.1016/j.mayocp.2019.01.018] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 27.0] [Reference Citation Analysis]
8 Lopez-Siles M, Aldeguer X, Sabat-Mir M, Serra-Pagès M, Duncan SH, Flint HJ, Garcia-Gil LJ, Martinez-Medina M. Evaluation of bacterial biomarkers to aid in challenging inflammatory bowel diseases diagnostics and subtype classification. World J Gastrointest Pathophysiol 2020; 11(3): 64-77 [PMID: 32435523 DOI: 10.4291/wjgp.v11.i3.64] [Reference Citation Analysis]
9 Na SY, Moon W. [Evolving Therapeutic Strategies in the Inflammatory Bowel Disease]. Korean J Gastroenterol 2018;71:61-8. [PMID: 29471602 DOI: 10.4166/kjg.2018.71.2.61] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Loy L, Roda G, Fiorino G, Allocca M, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S. Detection and management of early stage inflammatory bowel disease: an update for clinicians. Expert Rev Gastroenterol Hepatol 2019;13:547-55. [PMID: 31007098 DOI: 10.1080/17474124.2019.1605291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Rizzo G, Pugliese D, Armuzzi A, Coco C. Anti-TNF alpha in the treatment of ulcerative colitis: A valid approach for organ-sparing or an expensive option to delay surgery? World J Gastroenterol 2014; 20(17): 4839-4845 [PMID: 24803795 DOI: 10.3748/wjg.v20.i17.4839] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
12 Olivera P, Spinelli A, Gower-Rousseau C, Danese S, Peyrin-Biroulet L. Surgical rates in the era of biological therapy: up, down or unchanged? Curr Opin Gastroenterol. 2017;33:246-253. [PMID: 28463854 DOI: 10.1097/mog.0000000000000361] [Cited by in Crossref: 39] [Cited by in F6Publishing: 8] [Article Influence: 9.8] [Reference Citation Analysis]
13 Argollo MC, Kotze PG, Spinelli A, Gomes TN, Danese S. The impact of biologics in surgical outcomes in ulcerative colitis. Best Practice & Research Clinical Gastroenterology 2018;32-33:79-87. [DOI: 10.1016/j.bpg.2018.05.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
14 van der Post S, Hansson GC. Membrane protein profiling of human colon reveals distinct regional differences. Mol Cell Proteomics 2014;13:2277-87. [PMID: 24889196 DOI: 10.1074/mcp.M114.040204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
15 Chiba M, Nakane K, Tsuji T, Tsuda S, Ishii H, Ohno H, Watanabe K, Obara Y, Komatsu M, Sugawara T. Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial. Perm J 2019;23. [PMID: 31050638 DOI: 10.7812/TPP/18-220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zacharopoulou E, Craviotto V, Fiorino G, Furfaro F, Zilli A, Gilardi D, Peyrin-Biroulet L, Danese S, Allocca M. Targeting the gut layers in Crohn's disease: mucosal or transmural healing? Expert Rev Gastroenterol Hepatol 2020;14:775-87. [PMID: 32515627 DOI: 10.1080/17474124.2020.1780914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Costello SP, Ghaly S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, O'Connor S, Connor SJ, Sparrow MP, Bampton P, Walsh AJ, Andrews JM; Australian Inflammatory Bowel Disease Association (AIBDA). Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients. Intern Med J 2015;45:659-66. [PMID: 25732268 DOI: 10.1111/imj.12732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Ruel J, Ruane D, Mehandru S, Gower-Rousseau C, Colombel JF. IBD across the age spectrum: is it the same disease? Nat Rev Gastroenterol Hepatol. 2014;11:88-98. [PMID: 24345891 DOI: 10.1038/nrgastro.2013.240] [Cited by in Crossref: 118] [Cited by in F6Publishing: 118] [Article Influence: 13.1] [Reference Citation Analysis]
19 Peyrin-biroulet L, Van Assche G, Armuzzi A, Garcia-alvarez L, Lara N, Black CM, Khalifa A, Cornillie F, Kachroo S. Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2017;15:1154-1161.e1. [DOI: 10.1016/j.cgh.2016.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
20 Strohl M, Gonczi L, Kurt Z, Bessissow T, L Lakatos P. Quality of care in inflammatory bowel diseases: What is the best way to better outcomes? World J Gastroenterol 2018; 24(22): 2363-2372 [PMID: 29904243 DOI: 10.3748/wjg.v24.i22.2363] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
21 Mosli M, Al Beshir M, Al-Judaibi B, Al-Ameel T, Saleem A, Bessissow T, Ghosh S, Almadi M. Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol 2014;20:81-101. [PMID: 24705146 DOI: 10.4103/1319-3767.129473] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
22 Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380:1606-1619. [PMID: 22914296 DOI: 10.1016/s0140-6736(12)60150-0] [Cited by in Crossref: 840] [Cited by in F6Publishing: 408] [Article Influence: 84.0] [Reference Citation Analysis]
23 Goyal S, Rampal R, Kedia S, Mahajan S, Bopanna S, Yadav DP, Jain S, Singh AK, Wari MN, Makharia G, Awasthi A, Ahuja V. Urinary potassium is a potential biomarker of disease activity in Ulcerative colitis and displays in vitro immunotolerant role. Sci Rep 2017;7:18068. [PMID: 29273710 DOI: 10.1038/s41598-017-18046-x] [Reference Citation Analysis]
24 Li W, Zhang L, Xu Q, Yang W, Zhao J, Ren Y, Yu Z, Ma L. Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid. Nutrients 2022;14:1069. [DOI: 10.3390/nu14051069] [Reference Citation Analysis]
25 Esmat S, El Nady M, Elfekki M, Elsherif Y, Naga M. Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt. World J Gastroenterol 2014; 20(3): 814-821 [PMID: 24574754 DOI: 10.3748/wjg.v20.i3.814] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
26 Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis. 2012;30 Suppl 3:67-72. [PMID: 23295694 DOI: 10.1159/000342608] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
27 Laurain P, Guillo L, D’amico F, Netter P, Danese S, Baumann C, Luc A, Clerc-urmes I, Sofos S, Peyrin-biroulet L. Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study. Clinical Gastroenterology and Hepatology 2021;19:1899-1905.e1. [DOI: 10.1016/j.cgh.2021.01.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Hao Y, Yzet C, McBride RB, Stock A, Tiratterra E, D'Errico A, Belluzzi A, Scaioli E, Gionchetti P, Roda G, Ungaro R, Colombel JF, Harpaz N, Ko HM. Baseline Histological Findings Do Not Predict the Risk of Subsequent Extension in Patients with Limited Ulcerative Colitis. Dig Dis Sci 2021. [PMID: 33934255 DOI: 10.1007/s10620-021-06970-y] [Reference Citation Analysis]
29 Liefferinckx C, Franchimont D. Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2018;24:1428-39. [PMID: 29788122 DOI: 10.1093/ibd/izy109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
30 Peyrin-biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'donnell S, Pariente B, Winer S, Hanauer S, Colombel J-. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology 2015;110:1324-38. [DOI: 10.1038/ajg.2015.233] [Cited by in Crossref: 937] [Cited by in F6Publishing: 820] [Article Influence: 133.9] [Reference Citation Analysis]
31 Gong SS, Fan YH, Wang SY, Han QQ, Lv B, Xu Y, Chen X, He YE. Mucosa repair mechanisms of Tong-Xie-Yao-Fang mediated by CRH-R2 in murine, dextran sulfate sodium-induced colitis. World J Gastroenterol 2018; 24(16): 1766-1778 [PMID: 29713130 DOI: 10.3748/wjg.v24.i16.1766] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Noviello D, Mager R, Roda G, Borroni RG, Fiorino G, Vetrano S. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. Front Immunol 2021;12:611256. [PMID: 34079536 DOI: 10.3389/fimmu.2021.611256] [Reference Citation Analysis]
33 Danese S, Fiorino G, Peyrin-biroulet L. Positioning Therapies in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:1280-1290.e1. [DOI: 10.1016/j.cgh.2020.01.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
34 Kolehmainen S, Lepistö A, Färkkilä M. Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. Scand J Gastroenterol 2019;54:707-11. [PMID: 31136207 DOI: 10.1080/00365521.2019.1620326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
35 Chandra A, Kanth R, Thareja S. Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up. Biologics 2019;13:191-200. [PMID: 31819364 DOI: 10.2147/BTT.S214518] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Mak WY, Buisson A, Andersen MJ Jr, Lei D, Pekow J, Cohen RD, Kahn SA, Pereira B, Rubin DT. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018;63:1294-1301. [PMID: 29468374 DOI: 10.1007/s10620-018-4980-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
37 Mosli M, Alfaer S, Almalaki T, Albeshry A, Aljehani S, Alshmrani B, Habib Z, Jawa H, Qari Y. Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes? Eur J Gastroenterol Hepatol 2019;31:80-5. [PMID: 30199472 DOI: 10.1097/MEG.0000000000001249] [Reference Citation Analysis]
38 Torres J, Danese S, Colombel JF. New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut. 2013;62:1642-1652. [PMID: 24104885 DOI: 10.1136/gutjnl-2012-303959] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
39 Zacharias P, Damião AOMC, Moraes AC, Teixeira FV, Ludvig JC, Nones RB, Saad-Hossne R, Sassaki LY, Silva RPLD, Facchin L, Olandoski M, Kotze PG. ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY. Arq Gastroenterol 2017;54:321-7. [PMID: 28977114 DOI: 10.1590/S0004-2803.201700000-51] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
40 Zhang ZJ, Qu HL, Zhao N, Wang J, Wang XY, Hai R, Li B. Assessment of Causal Direction Between Gut Microbiota and Inflammatory Bowel Disease: A Mendelian Randomization Analysis. Front Genet 2021;12:631061. [PMID: 33679893 DOI: 10.3389/fgene.2021.631061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Llaó J, Naves JE, Ruiz-cerulla A, Marín L, Mañosa M, Rodríguez-alonso L, Cabré E, Garcia-planella E, Guardiola J, Domènech E. Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. Journal of Crohn's and Colitis 2014;8:1523-8. [DOI: 10.1016/j.crohns.2014.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
42 Tomar SK, Kedia S, Singh N, Upadhyay AD, Kamat N, Bopanna S, Yadav DP, Goyal S, Jain S, Makharia G, Ahuja V. Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease. JGH Open 2019;3:302-9. [PMID: 31406923 DOI: 10.1002/jgh3.12160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
43 Bielefeldt K. Factors influencing admission and outcomes in gastroparesis. Neurogastroenterol Motil. 2013;25:389-398, e294. [PMID: 23360151 DOI: 10.1111/nmo.12079] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
44 Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41:1094-1103. [PMID: 25809869 DOI: 10.1111/apt.13175] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
45 Paine ER. Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:161-168. [PMID: 24879406 DOI: 10.1093/gastro/gou028] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
46 Geers J, Bislenghi G, D'Hoore A, Wolthuis AM. Surgical Management of an Ileal J-Pouch-Anal Anastomosis Volvulus. Dis Colon Rectum 2019;62:1014-9. [PMID: 31283595 DOI: 10.1097/DCR.0000000000001403] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
47 Gomes TNF, de Azevedo FS, Argollo M, Miszputen SJ, Ambrogini O Jr. Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil. Clin Exp Gastroenterol 2021;14:91-102. [PMID: 33762838 DOI: 10.2147/CEG.S288688] [Reference Citation Analysis]
48 Duricova D, Burisch J, Jess T, Gower-Rousseau C, Lakatos PL;  ECCO-EpiCom. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohns Colitis. 2014;8:1351-1361. [PMID: 24951261 DOI: 10.1016/j.crohns.2014.05.006] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
49 Mackiewicz T, Sowa A, Fichna J. Biomarkers for Early Detection of Colitis-associated Colorectal Cancer - Current Concepts, Future Trends. Curr Drug Targets 2021;22:137-45. [PMID: 32077822 DOI: 10.2174/1389450121666200220123844] [Reference Citation Analysis]
50 Gisbert JP, Barreiro-de Acosta M, Esteve M, García-Sánchez V, Gomollón F, Guardiola J, Hinojosa J, Martín Arranz MD, Minguez M, Taxonera C, Vera I. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project. Inflamm Bowel Dis 2016;22:583-98. [PMID: 26529561 DOI: 10.1097/MIB.0000000000000617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Zhang Z, Yu PF, Gu GL, Zhang YH, Wang YM, Dong ZW, Yang HR. Diffuse invasive signet ring cell carcinoma in total colorectum caused by ulcerative colitis: A case report and review of literature. World J Clin Cases 2022; 10(5): 1729-1737 [DOI: 10.12998/wjcc.v10.i5.1729] [Reference Citation Analysis]
52 Qiu Y, Chen B, Li Y, Xiong S, Zhang S, He Y, Zeng Z, Ben-Horin S, Chen M, Mao R. Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study. BMC Gastroenterol 2019;19:7. [PMID: 30630426 DOI: 10.1186/s12876-018-0928-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
53 Reinglas J, Restellini S, Gonczi L, Kurti Z, Verdon C, Nene S, Kohen R, Afif W, Bessissow T, Wild G, Seidman E, Bitton A, Lakatos PL. Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic. Dig Liver Dis. 2019;51:340-345. [PMID: 30591367 DOI: 10.1016/j.dld.2018.11.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
54 le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology 2022:S0016-5085(21)04067-1. [PMID: 34995529 DOI: 10.1053/j.gastro.2021.09.076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Kruis W, Neshta V, Pesegova M, Alekseeva O, Andreev P, Datsenko O, Levchenko O, Abdulkhakov S, Lozynskyy Y, Mostovoy Y, Soloviev K, Dorofeyev AE, Vieth M, Stiess M, Greinwald R, Mohrbacher R, Siegmund B. Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis. Clin Gastroenterol Hepatol 2019; 17: 98-106. e4. [PMID: 29702300 DOI: 10.1016/j.cgh.2018.04.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
56 Li Y, Yang X, Yuan J, Lin R, Tian Y, Li Y, Zhang Y, Wang X, Xie Y, Wang S, Zheng X. Ilex rotunda Thunb Protects Against Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Restoring the Intestinal Mucosal Barrier and Modulating the Oncostatin M/Oncostatin M Receptor Pathway. Front Pharmacol 2022;13:819826. [DOI: 10.3389/fphar.2022.819826] [Reference Citation Analysis]
57 Liu WX, Gu SZ, Zhang S, Ren Y, Sang LX, Dai C. Angiopoietin and vascular endothelial growth factor expression in colorectal disease models. World J Gastroenterol 2015; 21(9): 2645-2650 [PMID: 25759532 DOI: 10.3748/wjg.v21.i9.2645] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
58 Chateau T, Feakins R, Marchal-Bressenot A, Magro F, Danese S, Peyrin-Biroulet L. Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.Am J Gastroenterol. 2020;115:179-189. [PMID: 31809296 DOI: 10.14309/ajg.0000000000000437] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
59 Yassin M, Sadowska Z, Tritsaris K, Kissow H, Hansen CHF, Forman JL, Rogler G, Troelsen JT, Pedersen AE, Olsen J. Rectal Insulin Instillation Inhibits Inflammation and Tumor Development in Chemically Induced Colitis. J Crohns Colitis 2018;12:1459-74. [PMID: 30137286 DOI: 10.1093/ecco-jcc/jjy112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
60 Yang ZH, Liu F, Zhu XR, Suo FY, Jia ZJ, Yao SK. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis. World J Gastroenterol 2021; 27(24): 3609-3629 [PMID: 34239273 DOI: 10.3748/wjg.v27.i24.3609] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
61 Troncone E, Monteleone G. The safety of non-biological treatments in Ulcerative Colitis. Expert Opin Drug Saf 2017;16:779-89. [PMID: 28608717 DOI: 10.1080/14740338.2017.1340936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
62 Al Khoury A, Xiao Y, Golovics PA, Kohen R, Afif W, Wild G, Friedman G, Galiatsatos P, Hilzenrat N, Szilagyi A, Wyse J, Cohen A, Bitton A, Bessissow T, Lakatos PL. Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort. Dig Liver Dis 2021;53:980-6. [PMID: 33640302 DOI: 10.1016/j.dld.2021.02.006] [Reference Citation Analysis]
63 Wang J, Wang X, Ma X, Xu B, Chen L, Chen C, Liu W, Liu Y, Xiang Z. Therapeutic effect of Patrinia villosa on TNBS-induced ulcerative colitis via metabolism, vitamin D receptor and NF-κB signaling pathways. J Ethnopharmacol 2022;:114989. [PMID: 35032589 DOI: 10.1016/j.jep.2022.114989] [Reference Citation Analysis]
64 Wang S, Liu Y, Yuan X, Yao L, Yang S, Ma R. Fecal bacteria from ulcerative colitis patients downregulate Tim-3-mediated inhibitory effects on monocytes in vitro. Microbial Pathogenesis 2019;128:147-52. [DOI: 10.1016/j.micpath.2018.12.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
65 Torres J, Caprioli F, Katsanos KH, Lobatón T, Micic D, Zerôncio M, Van Assche G, Lee JC, Lindsay JO, Rubin DT, Panaccione R, Colombel JF. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis 2016;10:1385-94. [PMID: 27282402 DOI: 10.1093/ecco-jcc/jjw116] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 10.5] [Reference Citation Analysis]
66 Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. Clin Gastroenterol Hepatol. 2020;18:14-23. [PMID: 31301452 DOI: 10.1016/j.cgh.2019.07.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
67 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 381] [Article Influence: 138.3] [Reference Citation Analysis]
68 Lee HS, Choe J, Kim SO, Lee SH, Lee HJ, Seo H, Kim GU, Seo M, Song EM, Hwang SW. Overall and cause-specific mortality in Korean patients with inflammatory bowel disease: A hospital-based cohort study. J Gastroenterol Hepatol. 2017;32:782-788. [PMID: 27637573 DOI: 10.1111/jgh.13596] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
69 Ohman L, Dahlén R, Isaksson S, Sjöling A, Wick MJ, Sjövall H, Van Oudenhove L, Simrén M, Strid H. Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease. Inflamm Bowel Dis. 2013;19:2433-2439. [PMID: 23966065 DOI: 10.1097/mib.0b013e3182a563cb] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
70 Lindsay JO, Bergman A, Patel AS, Alesso SM, Peyrin-biroulet L. Systematic review: the financial burden of surgical complications in patients with ulcerative colitis. Aliment Pharmacol Ther 2015;41:1066-78. [DOI: 10.1111/apt.13197] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
71 Calvet X, Argüelles-Arias F, López-Sanromán A, Cea-Calvo L, Juliá B, de Santos CR, Carpio D. Patients' perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain. Patient Prefer Adherence 2018;12:1815-23. [PMID: 30271125 DOI: 10.2147/PPA.S175026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
72 Moore AC, Huang VW, Bourdages R, Fedorak RN, Reinhard C, Leung Y, Bressler B, Rosenfeld G. IBDoc Canadian User Performance Evaluation. Inflamm Bowel Dis 2019;25:1107-14. [PMID: 30535387 DOI: 10.1093/ibd/izy357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
73 Chiba M, Nakane K, Tsuji T, Tsuda S, Ishii H, Ohno H, Watanabe K, Ito M, Komatsu M, Yamada K, Sugawara T. Relapse Prevention in Ulcerative Colitis by Plant-Based Diet Through Educational Hospitalization: A Single-Group Trial. Perm J 2018;22:17-167. [PMID: 30005726 DOI: 10.7812/TPP/17-167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
74 Almofarreh A, Sheerah HA, Arafa A, Ahamed SS, Alzeer O, Al-hunaishi W, Mhimed MM, Al-hazmi A, Lim SH. Beverage Consumption and Ulcerative Colitis: A Case-Control Study from Saudi Arabia. IJERPH 2022;19:2287. [DOI: 10.3390/ijerph19042287] [Reference Citation Analysis]
75 Zhu Y, Yang S, Zhao N, Liu C, Zhang F, Guo Y, Liu H. CXCL8 chemokine in ulcerative colitis. Biomed Pharmacother 2021;138:111427. [PMID: 33706134 DOI: 10.1016/j.biopha.2021.111427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
76 Fernández-clotet A, Castro-poceiro J, Panés J. JAK Inhibition: The Most Promising Agents in the IBD Pipeline? CPD 2019;25:32-40. [DOI: 10.2174/1381612825666190405141410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
77 Wang S, Wang J, Ma R, Yang S, Fan T, Cao J, Wang Y, Ma W, Yang W, Wang F, Zhang H. IL-10 enhances T cell survival and is associated with faster relapse in patients with inactive ulcerative colitis. Mol Immunol 2020;121:92-8. [PMID: 32193038 DOI: 10.1016/j.molimm.2020.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Baehler C, Brüngger B, Blozik E, Vavricka SR, Schoepfer AM. Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis. Inflamm Intest Dis 2019;4:144-53. [PMID: 31768387 DOI: 10.1159/000502205] [Reference Citation Analysis]
79 Shi G, Jiang H, Feng J, Zheng X, Zhang D, Jiang C, Zhang J. Aloe vera mitigates dextran sulfate sodium-induced rat ulcerative colitis by potentiating colon mucus barrier. J Ethnopharmacol 2021;279:114108. [PMID: 33839199 DOI: 10.1016/j.jep.2021.114108] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
80 Peyrin-biroulet L, Germain A, Patel AS, Lindsay JO. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. Aliment Pharmacol Ther 2016;44:807-16. [DOI: 10.1111/apt.13763] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 10.7] [Reference Citation Analysis]
81 Gonczi L, Bessissow T, Lakatos PL. Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”? World J Gastroenterol 2019; 25(41): 6172-6189 [PMID: 31749591 DOI: 10.3748/wjg.v25.i41.6172] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
82 Fradet C, Kern J, Atanasov P, Wirth D, Borsi A. Impact of surgery and its complications in ulcerative colitis patients in clinical practice: A systematic literature review of real-world evidence in Europe. International Journal of Surgery Open 2020;22:22-32. [DOI: 10.1016/j.ijso.2019.11.010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]